Application of 3D Mass Spectrometry Imaging to TKIs

Lavinia Morosi, Silvia Giordano, Francesca Falcetta, Roberta Frapolli, Simonetta A. Licandro, Cristina Matteo, Massimo Zucchetti, Paolo Ubezio, Eugenio Erba, Sonja Visentin, Maurizio D'Incalci, Enrico Davoli

Research output: Contribution to journalArticlepeer-review


Mass spectrometry imaging (MSI) allows visualization of endogenous and exogenous compound in tissue sections based on its molecular mass. The 3D reconstruction by MSI provides a more informative description of the tumor drug distribution compared to the high-performance liquid chromatography method, highlighting the heterogeneity of intratumor drug concentration. This additional information can be important in understanding chemoresistance to target agents. Here, we present the 3D visualization of the tyrosine kinase inhibitor (TKI), imatinib, in a xenograft model of resistant malignant pleural mesothelioma.

Original languageEnglish
Pages (from-to)748-751
Number of pages4
JournalClinical Pharmacology and Therapeutics
Issue number5
Publication statusPublished - Nov 1 2017

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Application of 3D Mass Spectrometry Imaging to TKIs'. Together they form a unique fingerprint.

Cite this